On October 20, 2025, Teva Pharmaceuticals International GmbH (“Teva”) announced a licensing agreement with Prestige BioPharma Ltd. (“Prestige BioPharma”) to commercialize TUZNUE® (trastuzumab), a biosimilar to Genentech’s HERCEPTIN (trastuzumab), in a majority of European countries. Under the license and supply agreement, Teva obtained the rights to market and distribute TUZNUE® across most European markets. Prestige BioPharma will maintain responsibility for manufacturing and supply.
In September 2024, Prestige BioPharma received marketing authorization for TUZNUE® from the European Commission (EC) for the treatment of breast cancer and metastatic gastric cancer.
The post Teva and Prestige Biopharma Enter Licensing Agreement to Commercialize Their Trastuzumab Biosimilar appeared first on Big Molecule Watch.